Real-world Experience With the Available Outpatient COVID-19 Therapies in Patients With Cancer: an Ambispective Cohort Study

NCT ID: NCT07241975

Last Updated: 2025-11-21

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 112 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-08-23
• Study Completion Date: 2024-12-31

Brief Summary

The real-life efficacy of early antiviral therapies in cancer patients with COVID-19 is largely uncharacterized. From these unresolved issues, it is therefore necessary to fill these knowledge gaps by assessing the efficacy and safety of these therapies in combination with anti-cancer therapies.

Conditions

Cancer Patients in Treatment Active Who Receive Early Out-patient Therapy Against SARS-CoV-2

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

1. Patients ≥ 18 years diagnosed with and/or treated for solid tumors at the department of Oncologia of the Fondazione IRCCS Policlinico San Matteo

2. Prospective patients (or their or legal guardians) who have the ability to understand and be willing to sign a written informed consent document

3. Retrospective patients who have signed the institutional document allowing the use of their data for research on their disease

Exclusion Criteria

• Patients who are unable to understand informed consent document

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER

Sponsor Role: lead

Responsible Party

Angioletta Lasagna

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Fondazione IRCCS Policlinico San Matteo, SC Oncologia

Pavia, Pavia, Italy

Countries

Italy

Other Identifiers

CO_TER

Identifier Type: -

Identifier Source: org_study_id